{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fbtki-therapy-for-cll-mcl-soho-2022-fQDHu00l","width":444,"version":"1.0","type":"rich","title":"New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/a2b4edfa-68a9-4f7f-ac44-96b100b026fd/pod501-mcl-cf-heme-podcast-soho.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/c902d4ad-ea76-477c-9c39-b6481a9b85ad\" height=\"200\" width=\"100%\" title=\"New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to expert perspectives on select studies from the SOHO 2022 Annual Meeting covering BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and the potential implications for clinical practice."}